Not Yet RecruitingNot Applicable

Prognostic Value of (DHODH) Expression in (HGSOC): A Comparative Study Between Neoadjuvant and Adjuvant Chemotherapy Settings

Egypt72 participantsStarted 2026-06-01

Plain-language summary

* To compare DHODH protein expression in HGSC tissues from patients undergoing Primary Debulking Surgery (PDS - Chemo-naive) versus Interval Debulking Surgery (IDS - Post-NACT). * To evaluate the association between DHODH expression and the degree of chemotherapy response (using the Chemotherapy Response Score - CRS for NACT cases). * To determine the prognostic value of DHODH expression in predicting Platinum-Free Interval (PFI) ,Progression -Free Survival (PFS) and Overall Survival (OS) across both groups.

Who can participate

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Histologically confirmed high-grade serous ovarian carcinoma * Availability of adequate FFPE tumor tissue * Known treatment modality (PDS or IDS) * Available clinical follow-up including platinum-free interval and survival data Exclusion Criteria: * Non-serous histological subtypes * Low-grade serous carcinoma * Inadequate tissue for immunohistochemistry * Missing clinical or follow-up data

What they're measuring

DHODH expression and patient survival

Timeframe: from diagnosis up to last follow up or death ( up to 96 months).

Trial details

NCT IDNCT07366242

SponsorHeba Ahmed Mohamed

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2027-06-01

Contact for this trial

heba ahmed mohamed, demonstrator

01151056041 heba.ahmed17199d@gmail.com

View on ClinicalTrials.gov More HGSOC trials